Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy.

ABSTRACT: The introduction in the clinic of immune checkpoint inhibitors (IOs) has represented an important improvement for the treatment of patients with advanced non-small cell lung cancer (NSCLC). These drugs have shown a higher activity as compared with chemotherapy in both first- and second-line of treatment, with some patients experiencing a long-lasting response. More recently, combinations of IOs have entered clinical trials in different tumor types including NSCLC. Nevertheless, IOs are active only in a subgroup of patients and biomarkers for appropriate patients' selection are urgently needed to offer the patients an effective therapy, and also to manage the costs. Tumor mutation burden (TMB) has powerfully emerged as a potential biomarker for immunotherapy and might enter the clinic in th

SUBMITTER: Fenizia F 

PROVIDER: S-EPMC6249618 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature